

Carolina S Ilkow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8850817/publications.pdf>

Version: 2024-02-01

40
papers

1,514
citations

430442

18
h-index

344852

36
g-index

42
all docs

42
docs citations

42
times ranked

1866
citing authors

#	ARTICLE	IF	CITATIONS
1	The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers. <i>Molecular Therapy</i> , 2012, 20, 749-758.	3.7	231
2	Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans. <i>Cancer Research</i> , 2013, 73, 1265-1275.	0.4	193
3	Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. <i>Nature Medicine</i> , 2015, 21, 530-536.	15.2	118
4	Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy. <i>EBioMedicine</i> , 2018, 31, 17-24.	2.7	115
5	Smac mimetics and innate immune stimuli synergize to promote tumor death. <i>Nature Biotechnology</i> , 2014, 32, 182-190.	9.4	104
6	VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. <i>Cancer Cell</i> , 2015, 28, 210-224.	7.7	77
7	Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques. <i>Molecular Therapy</i> , 2015, 23, 1066-1076.	3.7	65
8	From Scourge to Cure: Tumour-Selective Viral Pathogenesis as a New Strategy against Cancer. <i>PLoS Pathogens</i> , 2014, 10, e1003836.	2.1	61
9	Maraba MG1 Virus Enhances Natural Killer Cell Function via Conventional Dendritic Cells to Reduce Postoperative Metastatic Disease. <i>Molecular Therapy</i> , 2014, 22, 1320-1332.	3.7	60
10	Rubella Virus Capsid Protein Interacts with Poly(A)-Binding Protein and Inhibits Translation. <i>Journal of Virology</i> , 2008, 82, 4284-4294.	1.5	53
11	Dimethyl fumarate potentiates oncolytic virotherapy through NF- κ B inhibition. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	44
12	Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. <i>Nature Communications</i> , 2015, 6, 6410.	5.8	42
13	The Rubella Virus Capsid Protein Inhibits Mitochondrial Import. <i>Journal of Virology</i> , 2010, 84, 119-130.	1.5	34
14	The Rubella Virus Capsid Is an Anti-Apoptotic Protein that Attenuates the Pore-Forming Ability of Bax. <i>PLoS Pathogens</i> , 2011, 7, e1001291.	2.1	33
15	Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2268.	1.8	24
16	Analyses of Phosphorylation Events in the Rubella Virus Capsid Protein: Role in Early Replication Events. <i>Journal of Virology</i> , 2006, 80, 6917-6925.	1.5	21
17	SARS-CoV-2 S1 NanoBIT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition. <i>Biosensors and Bioelectronics</i> , 2021, 180, 113122.	5.3	21
18	Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization. <i>Membranes</i> , 2020, 10, 215.	1.4	20

#	ARTICLE	IF	CITATIONS
19	Modulation of signaling pathways by RNA virus capsid proteins. <i>Cellular Signalling</i> , 2008, 20, 1227-1236.	1.7	19
20	Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2ÂS for viral entry. <i>Molecular Therapy</i> , 2021, 29, 1984-2000.	3.7	19
21	Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies. <i>Molecular Therapy - Oncolytics</i> , 2019, 14, 179-187.	2.0	16
22	Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and TÂcell immune response against SARS-CoV-2 infection. <i>Molecular Therapy</i> , 2022, 30, 1885-1896.	3.7	16
23	Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy. <i>Nature Communications</i> , 2022, 13, 1898.	5.8	16
24	Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis. <i>Cancers</i> , 2020, 12, 2042.	1.7	14
25	A Viro-Immunotherapy Triple Play for the Treatment of Glioblastoma. <i>Cancer Cell</i> , 2017, 32, 133-134.	7.7	13
26	Rubella virus capsid protein: a small protein with big functions. <i>Future Microbiology</i> , 2010, 5, 571-584.	1.0	11
27	Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16027.	2.0	11
28	Phosphorylation and membrane association of the Rubella virus capsid protein is important for its anti-apoptotic function. <i>Cellular Microbiology</i> , 2014, 16, 1201-1210.	1.1	9
29	Luciferase-Based Biosensors in the Era of the COVID-19 Pandemic. <i>ACS Nanoscience Au</i> , 2021, 1, 15-37.	2.0	9
30	Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference. , 2018, 6, 62.		8
31	Redirecting oncolytic viruses: Engineering opportunists to take control of the tumour microenvironment. <i>Cytokine and Growth Factor Reviews</i> , 2020, 56, 102-114.	3.2	7
32	A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion. <i>Nanomaterials</i> , 2021, 11, 807.	1.9	7
33	Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 507-521.	2.0	7
34	Identification of FDA-approved Bifonazole as SARS-CoV-2 blocking agent following a bioreporter drug screen. <i>Molecular Therapy</i> , 2022, , .	3.7	5
35	Oncolytic Virus Immunotherapy. <i>Cancers</i> , 2021, 13, 3672.	1.7	4
36	Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1365-1378.	1.2	2

#	ARTICLE	IF	CITATIONS
37	Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter. Journal of Visualized Experiments, 2021, , .	0.2	1
38	Achieving efficient systemic delivery of oncolytic Vaccinia virus. Immunobiology, 2012, 217, 1135.	0.8	0
39	Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection. Journal of Visualized Experiments, 2021, , .	0.2	0
40	Generating Primary Models of Human Cancer to Aid in the Development of Clinically Relevant Oncolytic Viruses. Methods in Molecular Biology, 2020, 2058, 271-284.	0.4	0